Pharmaceutical

Aclaris Therapeutics (NASDAQ:ACRS) announced positive results from the 3-month, post-treatment, follow-up evaluation period of its twice-weekly placebo-controlled trial (WART-203) of A-101 45% topical solution (A-101 45%), an investigational new drug consisting of a proprietary high-concentration hydrogen peroxide topical solution being developed as a prescription treatment for common warts (verruca vulgaris). As quoted in the press …

Aclaris Therapeutics (NASDAQ:ACRS) announced positive results from the 3-month, post-treatment, follow-up evaluation period of its twice-weekly placebo-controlled trial (WART-203) of A-101 45% topical solution (A-101 45%), an investigational new drug consisting of a proprietary high-concentration hydrogen peroxide topical solution being developed as a prescription treatment for common warts (verruca vulgaris).

As quoted in the press release:

WART-203 evaluated the safety and efficacy of A-101 45% as compared to placebo (vehicle) in a randomized, double-blind, vehicle-controlled trial with a 3-month post-treatment follow-up period. This 3-month follow-up period was designed to understand the clinical effect of the twice weekly treatment regimen for 8 weeks and durability of the clinical effect.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20099.81+400.76
TSXV696.65+29.40
DOW32196.66+466.36
S&P 5004023.89+93.81
NASD11805.00+434.04
ASX7075.10+134.10

COMMODITIES

Commodities
Gold1799.77-12.54
Silver21.10-0.11
Copper4.180.00
Palladium1930.50-14.50
Platinum938.18-7.82
Oil109.57-0.92
Heating Oil3.71-0.05
Natural Gas7.85+0.19

DOWNLOAD FREE REPORTS

×